查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800247

全球显影剂市场 - 2025 年至 2030 年预测

Global Contrast Agent Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

显影剂市场预计将从 2025 年的 70.38 亿美元成长到 2030 年的 99.07 亿美元，复合年增长率为 7.08%。

由于慢性病盛行率上升以及对超音波、X 光、MRI 和 CT 等诊断影像的需求不断增长，显影剂市场预计将在 2025 年至 2030 年间大幅成长。显影剂在医疗图像影像中起着重要作用，可提高影像清晰度并支援准确的诊断和治疗，尤其是在影像引导程式 (IGS) 中。市场受到成像技术的进步、医疗保健投资的增加以及创新显影剂研发倡议的增加的推动。北美占有很大份额，而亚太地区预计将因其不断扩大的医疗保健基础设施而快速成长。挑战包括显影剂的高成本和潜在的副作用。

市场驱动因素

慢性病增多

癌症、心血管疾病和糖尿病等慢性疾病的日益普及是显影剂市场的主要驱动力。美国癌症协会报告称，2023年美国男性新增癌症病例1,013,310例，美国新增癌症病例948,000例，凸显了对先进诊断工具日益增长的需求。这些治疗需要精确的影像来进行诊断和製定治疗计划，从而推动了对CT和MRI扫描等显影剂的需求。合併症的高发生率也要求增强影像学检查能力，这进一步推动了市场成长。

诊断影像需求不断成长

随着公众意识的提升以及CT和MRI等影像设备的普及，诊断影像需求激增，这推动了显影剂市场的发展。影像导引手术因其即时视觉化、改善手术效果和诊断准确性而日益普及。显影剂技术创新正在提升影像品质和病患安全性，从而支持市场扩张。微创手术的兴起进一步增加了对用于精准诊断的显影剂的需求。

加大研发力度

研发投入的不断增加为显影剂剂的新型应用创造了机会。企业、研究机构和学术机构之间的合作正在推动更安全、更有效、副作用更少的显影剂的开发。这些努力旨在扩大显影剂在先进MRI和光谱CT成像等新应用中的使用，满足尚未满足的临床需求，并改善患者预后，从而推动市场成长。

市场限制

显影剂市场面临先进影像处理和显影剂高昂成本的挑战。某些显影剂可能有副作用，例如过敏反应和肾毒性，这引发了安全隐患，需要严格的测试并遵守相关法规。此外，供应链限制和监管复杂性可能会阻碍市场的扩充性。透过经济高效的创新和更安全的配方来应对这些挑战，对于实现永续成长至关重要。

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章 全球显影剂市场（按类型）

  • 介绍
  • 碘化
  • 钡基
  • 微气泡
  • 钆基

第六章 全球显影剂市场（按类型划分）

  • 介绍
  • X射线/CT
  • MRI
  • 超音波

第七章 全球显影剂市场（依给药途径）

  • 介绍
  • 血管内
  • 口服
  • 直肠
  • 其他的

第 8 章 全球造影显影剂）

  • 介绍
  • 肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 胃肠道疾病
  • 肾臟疾病
  • 肌肉骨骼疾病
  • 其他的

第九章全球显影剂市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章：公司简介

  • Guerbet Group
  • Bayer AG
  • Lantheus Medical Imaging, Inc.
  • Bracco Diagnostic, Inc.
  • GE
  • Curadel, LLC
  • Daiichi Sankyo Company, Limited
  • Magnus Health
  • Spago Nanomedical AB
  • JB Chemicals & Pharmaceuticals Ltd

第十二章调查方法

简介目录
Product Code: KSI061612094

The global contrast agent market is expected to grow from USD 7.038 billion in 2025 to USD 9.907 billion in 2030, at a CAGR of 7.08%.

The global contrast agent market is poised for significant growth from 2025 to 2030, driven by the rising prevalence of chronic diseases and increasing demand for diagnostic imaging procedures such as ultrasonography, X-rays, MRI, and CT scans. Contrast agents, critical for enhancing image clarity in medical imaging, support accurate diagnosis and treatment, particularly in image-guided procedures (IGS). The market is propelled by advancements in imaging technology, growing healthcare investments, and rising R&D initiatives for innovative contrast agents. North America holds a significant market share, while Asia-Pacific is expected to grow rapidly due to expanding healthcare infrastructure. Challenges include high costs and potential adverse effects of contrast agents.

Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic conditions, such as cancer, cardiovascular diseases, and diabetes, is a primary driver of the contrast agent market. In 2023, the American Cancer Society reported 1,010,310 new cancer cases in males and 948,000 in females in the United States, highlighting the growing need for advanced diagnostic tools. Conditions like these require precise imaging for diagnosis and treatment planning, boosting demand for contrast agents in procedures like CT and MRI scans. The high prevalence of comorbidities necessitates enhanced imaging capabilities, further driving market growth.

Growing Demand for Diagnostic Imaging

The surge in demand for diagnostic imaging, driven by public awareness and improved accessibility to modalities like CT and MRI, is fueling the contrast agent market. Image-guided procedures are gaining popularity due to their ability to provide real-time visualization, improving surgical outcomes and diagnostic accuracy. Innovations in contrast media, such as iso-osmolar agents, enhance imaging quality and patient safety, supporting market expansion. The growing adoption of minimally invasive procedures further amplifies the need for contrast agents to ensure precise diagnostics.

Rising R&D Initiatives

Increased investment in research and development is creating opportunities for novel contrast agent applications. Collaborative efforts between companies, research institutions, and academic bodies are focused on developing safer, more effective agents with fewer side effects. These initiatives aim to expand the use of contrast agents in emerging applications, such as advanced MRI and spectral CT imaging, driving market growth by addressing unmet clinical needs and improving patient outcomes.

Market Restraints

The contrast agent market faces challenges due to the high cost of advanced imaging procedures and contrast media, which can limit accessibility in cost-sensitive regions. Potential adverse effects, such as allergic reactions or nephrotoxicity associated with certain contrast agents, pose safety concerns, necessitating rigorous testing and regulatory compliance. Additionally, supply chain constraints and regulatory complexities may hinder market scalability. Addressing these challenges through cost-effective innovations and safer formulations will be critical for sustained growth.

Market Segmentation

By Type

The market is segmented into iodinated, gadolinium-based, barium-based, and microbubble contrast agents. Iodinated agents dominate due to their widespread use in CT imaging, while gadolinium-based agents are critical for MRI scans. Microbubble agents are gaining traction in ultrasound imaging for their ability to enhance vascular visualization.

By Application

The market includes diagnostic imaging (CT, MRI, ultrasound) and image-guided procedures. Diagnostic imaging holds the largest share, driven by the rising need for accurate diagnosis in chronic disease management. Image-guided procedures are a fast-growing segment due to their increasing use in minimally invasive surgeries.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads, driven by a robust healthcare sector, high cancer prevalence, and product innovations like Fresenius Kabi's FDA-approved generic iodixanol contrast agent launched in 2023. Asia-Pacific is expected to grow rapidly, fueled by expanding healthcare infrastructure and rising chronic disease rates in countries like China and India.

The contrast agent market is set for robust growth from 2025 to 2030, driven by the rising prevalence of chronic diseases, increasing demand for diagnostic imaging, and R&D advancements. Despite challenges like high costs and safety concerns, the market's outlook is positive, particularly in North America and Asia-Pacific. Industry players must focus on developing safer, cost-effective agents and leveraging collaborations to meet the growing demand for advanced imaging solutions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Type

  • Iodinated
  • Barium-based
  • Microbubble
  • Gadolinium-based

By Modality

  • X-ray/CT
  • MRI
  • Ultrasound

By Route of Administration

  • Intravascular
  • Oral
  • Rectal
  • Others

By Indication

  • Oncology
  • Cardiovascular Disease
  • Neurological Disorders
  • Gastrointestinal Disorders
  • Nephrological Disorders
  • Musculoskeletal Disorders
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CONTRAST AGENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Iodinated
  • 5.3. Barium-based
  • 5.4. Microbubble
  • 5.5. Gadolinium-based

6. GLOBAL CONTRAST AGENT MARKET BY MODALITY

  • 6.1. Introduction
  • 6.2. X-ray/CT
  • 6.3. MRI
  • 6.4. Ultrasound

7. GLOBAL CONTRAST AGENT MARKET BY ROUTE OF ADMINISTRATION

  • 7.1. Introduction
  • 7.2. Intravascular
  • 7.3. Oral
  • 7.4. Rectal
  • 7.5. Others

8. GLOBAL CONTRAST AGENT MARKET BY INDICATION

  • 8.1. Introduction
  • 8.2. Oncology
  • 8.3. Cardiovascular Disease
  • 8.4. Neurological Disorders
  • 8.5. Gastrointestinal Disorders
  • 8.6. Nephrological Disorders
  • 8.7. Musculoskeletal Disorders
  • 8.8. Others

9. GLOBAL CONTRAST AGENT MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East & Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Guerbet Group
  • 11.2. Bayer AG
  • 11.3. Lantheus Medical Imaging, Inc.
  • 11.4. Bracco Diagnostic, Inc.
  • 11.5. GE
  • 11.6. Curadel, LLC
  • 11.7. Daiichi Sankyo Company, Limited
  • 11.8. Magnus Health
  • 11.9. Spago Nanomedical AB
  • 11.10. J.B. Chemicals & Pharmaceuticals Ltd

12. RESEARCH METHODOLOGY